Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Gossamer Bio (GOSS) EBITDA: 2022-2025

Historic EBITDA for Gossamer Bio (GOSS) over the last 4 years, with Sep 2025 value amounting to -$48.2 million.

  • Gossamer Bio's EBITDA fell 48.36% to -$48.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$159.0 million, marking a year-over-year decrease of 117.09%. This contributed to the annual value of -$55.0 million for FY2024, which is 69.38% up from last year.
  • Gossamer Bio's EBITDA amounted to -$48.2 million in Q3 2025, which was down 13.41% from -$42.5 million recorded in Q2 2025.
  • Over the past 5 years, Gossamer Bio's EBITDA peaked at $49.3 million during Q2 2024, and registered a low of -$59.4 million during Q3 2022.
  • Its 3-year average for EBITDA is -$33.1 million, with a median of -$42.2 million in 2024.
  • In the last 5 years, Gossamer Bio's EBITDA surged by 215.99% in 2024 and then tumbled by 186.21% in 2025.
  • Gossamer Bio's EBITDA (Quarterly) stood at -$55.8 million in 2022, then increased by 14.12% to -$47.9 million in 2023, then soared by 38.16% to -$29.6 million in 2024, then tumbled by 48.36% to -$48.2 million in 2025.
  • Its EBITDA was -$48.2 million in Q3 2025, compared to -$42.5 million in Q2 2025 and -$38.7 million in Q1 2025.